Compare Stocks: SXTP, DARE, CTXR, and ZIVO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$0.57 -4.9%	$0.60	$0.47 ▼ $2.19	$16.42M	1	250,095 shs	222,928 shs
DARE Dare Bioscience	$0.81 -5.0%	$1.02	$0.69 ▼ $3.78	$16.72M	1.01	306,178 shs	99,701 shs
SXTP 60 Degrees Pharmaceuticals	$1.16 +11.5%	$1.15	$0.84 ▼ $8.62	$3.66M	2.54	69,212 shs	53,778 shs
ZIVO ZIVO Bioscience	$3.60 +1.4%	$4.00	$1.11 ▼ $17.50	$15.17M	0.16	2,868 shs	1,975 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	-4.95%	+1.54%	-1.18%	+4.31%	-50.56%
DARE Dare Bioscience	-5.01%	+11.29%	+0.74%	-59.63%	-60.81%
SXTP 60 Degrees Pharmaceuticals	+11.54%	+25.54%	+7.41%	-29.27%	-79.14%
ZIVO ZIVO Bioscience	+1.41%	+4.20%	-15.69%	+14.29%	-72.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$0.57 -4.9%	$0.60	$0.47 ▼ $2.19	$16.42M	1	250,095 shs	222,928 shs
DARE Dare Bioscience	$0.81 -5.0%	$1.02	$0.69 ▼ $3.78	$16.72M	1.01	306,178 shs	99,701 shs
SXTP 60 Degrees Pharmaceuticals	$1.16 +11.5%	$1.15	$0.84 ▼ $8.62	$3.66M	2.54	69,212 shs	53,778 shs
ZIVO ZIVO Bioscience	$3.60 +1.4%	$4.00	$1.11 ▼ $17.50	$15.17M	0.16	2,868 shs	1,975 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	-4.95%	+1.54%	-1.18%	+4.31%	-50.56%
DARE Dare Bioscience	-5.01%	+11.29%	+0.74%	-59.63%	-60.81%
SXTP 60 Degrees Pharmaceuticals	+11.54%	+25.54%	+7.41%	-29.27%	-79.14%
ZIVO ZIVO Bioscience	+1.41%	+4.20%	-15.69%	+14.29%	-72.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTXR Citius Pharmaceuticals	2.40	Hold	$5.00	779.35% Upside
DARE Dare Bioscience	2.33	Hold	$6.50	705.05% Upside
SXTP 60 Degrees Pharmaceuticals	2.00	Hold	$13.85	1,093.97% Upside
ZIVO ZIVO Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SXTP, DARE, CTXR, and ZIVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	CTXR Citius Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/21/2026	SXTP 60 Degrees Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/16/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/14/2026	DARE Dare Bioscience	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1.00
8/25/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	CTXR Citius Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/19/2026	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	DARE Dare Bioscience	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	DARE Dare Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	CTXR Citius Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTXR Citius Pharmaceuticals	$7.11M	2.20	N/A	N/A	$4.29 per share	0.13
DARE Dare Bioscience	$1.03M	15.42	N/A	N/A	$0.20 per share	4.04
SXTP 60 Degrees Pharmaceuticals	$1.41M	2.90	N/A	N/A	($5.85) per share	-0.20
ZIVO ZIVO Bioscience	$15.85K	957.35	N/A	N/A	($0.81) per share	-4.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTXR Citius Pharmaceuticals	-$37.43M	-$1.67	N/A	N/A	N/A	N/A	-59.57%	-34.47%	N/A
DARE Dare Bioscience	-$13.40M	-$0.70	N/A	N/A	N/A	-803.80%	-748.30%	-38.75%	11/12/2026 (Estimated)
SXTP 60 Degrees Pharmaceuticals	-$7.36M	-$4.82	N/A	N/A	N/A	-650.21%	N/A	-136.81%	11/12/2026 (Estimated)
ZIVO ZIVO Bioscience	-$7.78M	-$1.40	N/A	N/A	N/A	N/A	N/A	-2,240.92%	12/2/2026 (Estimated)

Latest SXTP, DARE, CTXR, and ZIVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	CTXR Citius Pharmaceuticals	-$0.36	-$0.34	+$0.02	-$0.34	$5.46 million	N/A
8/14/2026	Q2 2026	SXTP 60 Degrees Pharmaceuticals	-$0.74	-$0.90	-$0.16	-$0.90	$0.21 million	$0.21 million
8/13/2026	Q2 2026	DARE Dare Bioscience	-$0.2967	-$0.20	+$0.0967	-$0.20	$0.00 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
SXTP 60 Degrees Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTXR Citius Pharmaceuticals	0.08	0.84	0.40
DARE Dare Bioscience	N/A	0.99	0.99
SXTP 60 Degrees Pharmaceuticals	N/A	2.32	1.78
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTXR Citius Pharmaceuticals	16.88%
DARE Dare Bioscience	6.70%
SXTP 60 Degrees Pharmaceuticals	7.96%
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
CTXR Citius Pharmaceuticals	4.99%
DARE Dare Bioscience	4.10%
SXTP 60 Degrees Pharmaceuticals	1.68%
ZIVO ZIVO Bioscience	48.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTXR Citius Pharmaceuticals	20	27.45 million	26.08 million	Optionable
DARE Dare Bioscience	24	19.67 million	18.86 million	Not Optionable
SXTP 60 Degrees Pharmaceuticals	3	3.52 million	3.46 million	Not Optionable
ZIVO ZIVO Bioscience	10	4.22 million	2.91 million	Not Optionable

SXTP, DARE, CTXR, and ZIVO Headlines

Recent News About These Companies

ZIVO Bioscience (NASDAQ:ZIVO) Stock Price Passes Below 200 Day Moving Average - Here's Why

September 19, 2026 | americanbankingnews.com

Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace

May 12, 2026 | businesswire.com

Zivo Bioscience Inc. Wt

April 11, 2026 | barrons.com

ZIVO Bioscience Provides Special Letter to Shareholders

March 27, 2026 | businesswire.com

Maxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)

December 15, 2025 | theglobeandmail.com

ZIVO Bioscience releases letter to shareholders

September 14, 2025 | wattagnet.comW

ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses

September 10, 2025 | businesswire.com

ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry

June 20, 2025 | businesswire.com

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7, 2025 | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6, 2025 | businesswire.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.comM

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.comM

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72

November 1, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP, DARE, CTXR, and ZIVO Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

$0.57 -0.03 (-4.95%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$0.57 +0.00 (+0.60%)

As of 09:10 AM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Dare Bioscience NASDAQ:DARE

$0.81 -0.04 (-5.01%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$0.82 +0.01 (+1.81%)

As of 09:06 AM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

60 Degrees Pharmaceuticals NASDAQ:SXTP

$1.16 +0.12 (+11.54%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.10 -0.06 (-5.52%)

As of 09:01 AM Eastern

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

ZIVO Bioscience NASDAQ:ZIVO

$3.60 +0.05 (+1.41%)

As of 09/23/2026 12:57 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTP, DARE, CTXR, and ZIVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTP, DARE, CTXR, and ZIVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTP, DARE, CTXR, and ZIVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP, DARE, CTXR, and ZIVO Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

Dare Bioscience NASDAQ:DARE

60 Degrees Pharmaceuticals NASDAQ:SXTP

ZIVO Bioscience NASDAQ:ZIVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTP, DARE, CTXR, and ZIVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTP, DARE, CTXR, and ZIVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTP, DARE, CTXR, and ZIVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP, DARE, CTXR, and ZIVO Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

Dare Bioscience NASDAQ:DARE

60 Degrees Pharmaceuticals NASDAQ:SXTP

ZIVO Bioscience NASDAQ:ZIVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools